EDSA Stock Price, Chart, Stats & News
Edesa Biotech, Inc. (EDSA) does not currently pay a dividend.
EDSA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.01% |
ROA | -53.13% |
ROE | -55.75% |
D/E | – |
Interest coverage ratio | – |
EDSA valuation
P/E | – |
P/S | – |
P/B | 3.33x |
P/CF | -5.85x |
P/FCF | -6.12x |
P/OCF | -5.85x |
PEG | -0.40x |
EV multiple | -7.80x |
About
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10.
Similar securities
Based on sector and market capitalization
